Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904020 · ClinicalTrials.gov registry record · Phase 4
A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 107
- Enrollment target
NCT00904020: Completed Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00904020 is a Phase 4 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904020, a Phase 4 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 107 participants
- Enrollment target
Study Summary
Patients with a diagnosis of postherpetic neuralgia (PHN), diabetic neuropathy (DN), or low back pain (LBP) who were currently receiving an analgesic regimen that contained gabapentin participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm® administered once daily (q24h) after 14 day in the treatment of PHN, DN, or LBP in patients who had a partial response to a regimen containing gabapentin.
Interventions
- DRUG Lidoderm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2002-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904020
The ClinicalTrials.gov registry entry for NCT00904020 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lidoderm is the first listed.
NCT00904020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904020 about?
NCT00904020 is a clinical study titled "A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain". Patients with a diagnosis of postherpetic neuralgia (PHN), diabetic neuropathy (DN), or low back pain (LBP) who were currently receiving an analgesic regimen that contained gabapentin participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm® administered once daily (q24h) af...
What is the current status of trial NCT00904020?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 107 participants. The study started on 2002-06.
What interventions are being tested in trial NCT00904020?
The interventions under investigation include: Lidoderm (DRUG).
Who is sponsoring clinical trial NCT00904020?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.